NuCana applies novel ProTide technology to transform some of the most widely prescribed chemotherapeutic agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and haematological tumors, they have significant shortcomings that limit their efficacy, and they are often poorly tolerated. Utilizing its proprietary technology, NuCana is developing new medicines, ProTides, designed to overcome the key limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. NuCana’s pipeline includes NUC-3373 and NUC-7738. NUC-3373 is a new chemical entity derived from 5-fluorouracil, a widely used chemotherapy agent, and NUC-7738 is a transformation of 3’-deoxyadenosine, a novel anti-cancer nucleoside analog. NuCana is listed on Nasdaq with the ticker: NCNA.